title: Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
abstract: Temozolomide (TMZ), a DNA methylating agent, is widely used in the adjuvant treatment of malignant gliomas. O6-methylguanine-DNA methyltranferase (MGMT), a DNA repair enzyme, is frequently discussed as the main factor that limits the efficacy of TMZ. Zoledronic acid (ZOL), which is clinically applied to treat cancer-induced bone diseases, appears to possess direct anti-tumor activity through apoptosis induction by inhibiting mevalonate pathway and prenylation of intracellular small G proteins. In this study, we evaluated whether ZOL can be effectively used as an adjuvant to TMZ in human malignant glioma cells that express MGMT. Malignant glioma cell lines, in which the expression of MGMT was detected, did not exhibit growth inhibition by TMZ even at a longer exposure. However, combination experiment of TMZ plus ZOL revealed that a supra-additive effect resulted in a significant decrease in cell growth. In combined TMZ/ZOL treatment, an increased apoptotic rate was apparent and significant activation of caspase-3 and cleavage of poly-(ADP-ribose) polymerase were observed compared with each single drug exposure. There were decreased amounts of Ras-GTP, MAPK and Akt phosphorylation and MGMT expression in the ZOL-treated cells. Subcutanous xenograft models showed significant decrease of tumor growth with combined TMZ/ZOL treatment. These results suggest that ZOL efficaciously inhibits activity of Ras in malignant glioma cells and potentiates TMZ-mediated cytotoxicity, inducing growth inhibition and apoptosis of malignant glioma cells that express MGMT and resistant to TMZ. Based on this work, combination of TMZ with ZOL might be a potential therapy in malignant gliomas that receive less therapeutic effects of TMZ due to cell resistance.
authors.affiliation: Department of Neurological Surgery, Wakayama Medical University School of Medicine, Wakayama, Japan; Shien-Lab, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Junya
authors.initials: J
authors.lastname: Fukai
authors.affiliation: Shien-Lab, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Koizumi
authors.affiliation: Department of Neurological Surgery, Wakayama Medical University School of Medicine, Wakayama, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Nakao
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004164:Diphosphonates / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005910:Glioma / Q000235:genetics / Q000473:pathology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D051379:Mice; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics*; D015398:Signal Transduction / Q000187:drug effects; D000077204:Temozolomide; D023041:Xenograft Model Antitumor Assays; D000077211:Zoledronic Acid; D018631:ras Proteins / Q000378:metabolism
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D018631:ras Proteins; D000077204:Temozolomide
references.citation: PLoS One. 2013 May 07;8(5):e62351
references.pmid: 23667469
references.citation: J Biol Chem. 1994 Dec 9;269(49):30761-4
references.pmid: 7983002
references.citation: Lung Cancer. 2005 Jan;47(1):31-9
references.pmid: 15603852
references.citation: Cancer Lett. 2007 Nov 8;257(1):16-35
references.pmid: 17697748
references.citation: Neuro Oncol. 2010 Jan;12(1):28-36
references.pmid: 20150365
references.citation: Drug Metab Dispos. 2008 Oct;36(10):2043-9
references.pmid: 18625688
references.citation: Int J Cancer. 1997 May 2;71(3):311-9
references.pmid: 9139860
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: Cancer Res. 2005 Jun 1;65(11):4861-9
references.pmid: 15930307
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Cancer Sci. 2004 Feb;95(2):186-92
references.pmid: 14965371
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Exp Cell Res. 2008 Apr 1;314(6):1193-201
references.pmid: 18282569
references.citation: Oncogene. 2007 Jan 11;26(2):186-97
references.pmid: 16819506
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Cancer Res. 2005 Aug 15;65(16):7429-35
references.pmid: 16103096
references.citation: Neuro Oncol. 2009 Aug;11(4):357-67
references.pmid: 19211933
references.citation: J Clin Oncol. 1998 Dec;16(12):3851-7
references.pmid: 9850030
references.citation: J Biol Chem. 1998 Dec 11;273(50):33533-9
references.pmid: 9837934
references.citation: Cancer Res. 2001 Mar 1;61(5):1957-63
references.pmid: 11280752
references.citation: PLoS One. 2013;8(1):e55665
references.pmid: 23383259
references.citation: Acta Neuropathol. 2007 Aug;114(2):121-33
references.pmid: 17588166
references.citation: Cancer Sci. 2008 Oct;99(10):2062-9
references.pmid: 19016767
references.citation: J Neurooncol. 2014 Jan;116(1):31-9
references.pmid: 24062140
references.citation: Br J Cancer. 2002 May 6;86(9):1479-86
references.pmid: 11986784
references.citation: Mol Cancer Ther. 2008 Sep;7(9):2768-78
references.pmid: 18790757
references.citation: J Clin Oncol. 2007 Sep 10;25(26):4127-36
references.pmid: 17827463
references.citation: Nature. 1993 Apr 15;362(6421):652-4
references.pmid: 8464518
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4189-99
references.pmid: 18757334